AI brief of an SEC Form 8-K · DuPont (DD)

DuPont agrees to $455 million North Carolina PFAS settlement payable over 15 years

Negative Impact 4 of 5 legal/regulatory Written later

On September 9, 2026, DuPont, Chemours and Corteva entered a settlement with the State of North Carolina and 11 local entities to resolve PFAS-related claims, including claims tied to the Fayetteville Works facility and AFFF-related contamination. The settlement is subject to entry of orders dismissing the covered claims, and DuPont recorded a probable loss of about $125 million in the second quarter of 2026, which the press release says is materially covered by existing accruals.

Key points

  • Aggregate cash payment of $455 million to the plaintiffs, payable over 15 years, shared under the 2021 MOU; $18 million is attributed to PFAS contamination unrelated to Fayetteville Works.
  • DuPont recorded a probable loss of about $125 million in Q2 2026 within discontinued operations, before Qnity Electronics' reimbursement of 44% of DuPont's share.
  • DuPont and Corteva will establish a $135 million Reserve Fund, accessible only if Chemours fails to perform under its 2019 Consent Order with the State.
  • Future MOU escrow contributions, including the one due in September 2026, will be considered satisfied by the New Jersey and North Carolina settlement payments.

The filing

CompanyDuPont (DD)
Form8-K, current report
Filed with the SECSep 10, 2026, 7:06 AM ET
Accession number0001666700-26-000055

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.